

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version 6.0 Revision Date: 12/13/2025 SDS Number: 5445458-00011 Date of last issue: 12/06/2025
Date of first issue: 02/20/2020

SECTION 1. IDENTIFICATION

Product name : Serum Gonadotrophin Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Hazards for the product as supplied

Reproductive toxicity : Category 1B

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

Hazards associated with a change in physical form:

Conditions	Hazards
If small particles are generated during further processing, handling or by other means.	May form combustible dust concentrations in air.

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360Fd May damage fertility. Suspected of damaging the unborn child.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version 6.0 Revision Date: 12/13/2025 SDS Number: 5445458-00011 Date of last issue: 12/06/2025
Date of first issue: 02/20/2020

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Gonadotropin, pregnant mare serum	9002-70-4*	$\geq 5 - \leq 34.7$	-

* Indicates that the identifier is a CAS No.

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage fertility. Suspected of damaging the unborn child.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
No information available.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Metal oxides
Oxides of phosphorus
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|---|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : | Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

- | | |
|------------------------|---|
| inert or nuisance dust | 50 Million particles per cubic foot
Value type (Form of exposure): TWA (total dust)
Basis: OSHA Z-3 |
| | 15 mg/m ³
Value type (Form of exposure): TWA (total dust)
Basis: OSHA Z-3 |
| | 5 mg/m ³
Value type (Form of exposure): TWA (respirable fraction)
Basis: OSHA Z-3 |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version 6.0 Revision Date: 12/13/2025 SDS Number: 5445458-00011 Date of last issue: 12/06/2025
Date of first issue: 02/20/2020

15 Million particles per cubic foot
Value type (Form of exposure): TWA (respirable fraction)
Basis: OSHA Z-3

Dust, nuisance dust and particulates 10 mg/m³
Value type (Form of exposure): PEL (Total dust)
Basis: CAL PEL

5 mg/m³
Value type (Form of exposure): PEL (respirable dust fraction)
Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Gonadotropin, pregnant mare serum	9002-70-4	TWA	4 µg/m ³ (OEB 4)	Internal
		Wipe limit	40 µg/100 cm ²	Internal

Engineering measures : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

	release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: powder
Color	: white
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Acute oral toxicity	: LD50 (Mouse): 120 mg/kg
Acute inhalation toxicity	: Remarks: No data available
Acute dermal toxicity	: Remarks: No data available
Acute toxicity (other routes of administration)	: LD50 (Mouse): > 1,700 mg/kg Application Route: Intravenous LD50 (Mouse): > 1,700 mg/kg Application Route: Subcutaneous LD50 (Rat): 500 mg/kg Application Route: Intravenous LD50 (Rat): 500 mg/kg Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks	: No data available
---------	---------------------

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks	: No data available
---------	---------------------

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

Respiratory sensitization

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Genotoxicity in vivo : Test Type: Cytogenetic assay
Species: Mouse
Application Route: Intraperitoneal injection
Result: positive
Remarks: Not classified due to data which are conclusive although insufficient for classification.

Carcinogenicity

Not classified based on available information.

Components:

Gonadotropin, pregnant mare serum:

Carcinogenicity - Assessment : No data available

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Components:

Gonadotropin, pregnant mare serum:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: LOAEL: 10 µg/kg
Result: Effects on fertility.
Remarks: May cause adverse reproductive effects.
Based on data from similar materials

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

Effects on fetal development : Remarks: May cause birth defects.
Based on data from similar materials

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments., Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Gonadotropin, pregnant mare serum:

Species	: Rat
NOAEL	: 1.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Days
Symptoms	: No adverse effects.

Species	: Rat
LOAEL	: 10 mg/kg
Application Route	: Oral
Exposure time	: 14 Days
Target Organs	: Reproductive organs

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Gonadotropin, pregnant mare serum:

Inhalation	: Symptoms: Headache, Fatigue, mood swings, altered mental status, Edema, Allergic reactions, Effects on fertility.
Skin contact	: Remarks: May produce an allergic reaction.
Ingestion	: Remarks: May be harmful if swallowed.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version 6.0 Revision Date: 12/13/2025 SDS Number: 5445458-00011 Date of last issue: 12/06/2025
Date of first issue: 02/20/2020

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging : Empty containers should be taken to an approved waste
handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

Components	CAS-No.	Component RQ (lbs)	Calculated product RQ (lbs)
Sodium phosphate, dihydrate	10028-24-7	5000	94339

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

D-Mannitol	69-65-8
Gonadotropin, pregnant mare serum	9002-70-4
Sodium phosphate, monobasic, dihydrate	13472-35-0
Sodium phosphate, dihydrate	10028-24-7

California List of Hazardous Substances

Sodium phosphate, dihydrate	10028-24-7
-----------------------------	------------

The ingredients of this product are reported in the following inventories:

AICS : not determined


CA. DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	*	0
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

CAL PEL : California permissible exposure limits for chemical contaminants (Title 8, Article 107)

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

CAL PEL / PEL : Permissible exposure limit
OSHA Z-3 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 12/13/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Serum Gonadotrophin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
6.0	12/13/2025	5445458-00011	Date of first issue: 02/20/2020

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8